Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 479 or AMG 655 with FOLFIRI in KRAS-mutant Metastatic Colorectal Cancer
NCT00813605Phase 2Completed
- Sponsor
- ImmunityBio, Inc.
- Start
- Mar 2009
- Primary completion
- Jan 2011
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of conatumumab, ganitumab in colorectal cancer (metastatic) (mCRC), sponsored by ImmunityBio, Inc.. Started Mar 2009; status: completed.
02
Drugs
conatumumabganitumab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT00813605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00813605.